Antibiotic Collaboration and Licensing Deals 2016-2024


Antibiotic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Antibiotic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibiotic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of antibiotic deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter antibiotic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 133 antibiotic deals announced since 2016 including financial terms where available including links to online deal records of actual antibiotic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of antibiotic dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibiotic dealmaking since 2016.

Chapter 3 provides an overview of the leading antibiotic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotic dealmaking with a brief summary followed by a comprehensive listing of antibiotic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibiotic deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of antibiotic partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibiotic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibiotic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibiotic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse antibiotic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Antibiotic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibiotic trends and structure of deals entered into by leading biopharma companies worldwide.

Antibiotic Collaboration and Licensing Deals includes:
•    Trends in antibiotic dealmaking in the biopharma industry
•    Directory of antibiotic deal records covering pharmaceutical and biotechnology
•    The leading antibiotic deals by value
•    Most active antibiotic licensing dealmakers

Antibiotic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Antibiotic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse antibiotic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in antibiotic dealmaking
2.1. Introduction
2.2. Antibiotic deals over the years
2.3. Most active antibiotic dealmakers
2.4. Antibiotic deals by deal type
2.5. Antibiotic deals by therapy area
2.6. Antibiotic deals by industry sector
2.7. Deal terms for antibiotic deals
2.7.1 Antibiotic deals headline values
2.7.2 Antibiotic deal upfront payments
2.7.3 Antibiotic deal milestone payments
2.7.4 Antibiotic royalty rates

Chapter 3 – Leading antibiotic deals
3.1. Introduction
3.2. Top antibiotic deals by value

Chapter 4 – Most active antibiotic dealmakers
4.1. Introduction
4.2. Most active antibiotic dealmakers
4.3. Most active antibiotic deals company profiles

Chapter 5 – Antibiotic contracts dealmaking directory
5.1. Introduction
5.2. Antibiotic contracts dealmaking directory

Chapter 6 – Antibiotic dealmaking by technology type

Deal directory

Deal directory – Antibiotic deals by company A-Z
Deal directory – Antibiotic deals by deal type
Deal directory – Antibiotic deals by therapy area

Deal type definitions

About Biopharma Research Ltd 
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Antibiotic deals since 2016
Figure 2: Active antibiotic dealmaking activity – 2016 - 2024
Figure 3: Antibiotic deals by deal type since 2016
Figure 4: Antibiotic deals by therapy area since 2016
Figure 5: Antibiotic deals by industry sector since 2016
Figure 6: Antibiotic deals with a headline value
Figure 7: Antibiotic deals with an upfront value
Figure 8: Antibiotic deals with a milestone value
Figure 9: Antibiotic deals with a royalty rate value
Figure 10: Top antibiotic deals by value since 2016
Figure 11: Most active antibiotic dealmakers 2016 - 2024
Figure 12: Antibiotic deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

3B Pharmaceuticals, Achaogen, Acurx Pharmaceuticals, Advanz Pharma, Allecra Therapeutics, Allergan, Amerigen Pharmaceuticals, Amicogen, AMR, Amyris, Antibiotic Research UK, Appili Therapeutics, Arrevus, Artizan Biosciences, AstraZeneca, Australian Research Council, Avails Medical, Basilea Pharmaceutica, Biomedical Advanced Research and Development Authority, Biophore Pharmaceuticals, BioVersys, Blacksmith Medicines, Boston Pharmaceuticals, Boston University, Boulos and Cooper Pharmaceuticals, Brii Biosciences, Bugworks, California Institute for Biomedical Research, CARB-X, Centre for Drug Research and Development (CDRD), Cepheid, Checkpoint Therapeutics, Chelexa Biosciences, Cidara Therapeutics, Citius Pharmaceuticals, Cleveland Clinic, Clinton Health Access Initiative, Correvio Pharma, Cosmo Pharmaceuticals, Crestone Pharma, CSPC Pharmaceutical Group, Cumberland Pharmaceuticals, Cystic Fibrosis Foundation, Dana-Farber Cancer Institute, Debiopharm, Decibel Therapeutics, Defense Threat Reduction Agency, Deinove, Department of Defense, Department of Health and Human Services, Dermin, Dr. Reddy's Laboratories, DSM Sinochem Pharmaceuticals, Entasis Therapeutics, Enterome Bioscience, Eurofarma, European Investment Bank, Everest Medicines, Evotec, Federal Ministry of Education and Research (BMBF), Flightpath Biosciences, Florida International University, Forge Therapeutics, Forsyth Institute, Foundation for Innovative New Diagnostics, Geom Therapeutics, Global Antibiotic Research and Development Partnership, GPCR Therapeutics, GSK, Hackensack Meridian Health, Harvard Medical School, Hasten Biopharmaceutic, Helmholtz Centre for Infection Research, Helperby Therapeutics, Hikma Pharmaceuticals, Hoffmann La Roche, Hoth Therapeutics, Hvidovre Hospital, Ichor Biologics, InfectoPharm, Infex Therapeutics, InfoRLife, Ingenza, Innosuisse, Innovate UK, Insmed Inc, Italfarmaco, Johns Hopkins University, Journey Medical, Kinnear Pharmaceuticals, Knauer Scientific Instruments, LegoChem Biosciences, LEO Pharma, Leukocare, LifeArc, Liverpool School of Tropical Medicine, Luminarie, Lysando, Macrolide Pharma, Magle Chemoswed, Matinas Biopharma, MD Anderson Cancer Center, Medicines Patent Pool Foundation, Melinta Therapeutics, Menarini, Merck and Co, Microbiotix, MicuRx Pharmaceuticals, Moleculin Biotech, Monash University, Nabriva Therapeutics, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, National Institutes of Health, Navamedic, Nosopharm, Novartis, Opal Therapeutics, OpGen, Oragenics, Oricula Therpeutics, Oxford Drug Design, Paratek Pharmaceuticals, Pfizer, Phico Therapeutics, Pieces Technologies, Polyphor, Prokaryotics, Q-linea AB, Qpex Biopharma, QureTech Bio, Recce Pharmaceuticals, Recida Therapeutics, RedHill Biopharma, RMX Biopharma, Roche, Sandoz, Saptalis Pharmaceuticals, SeLux Diagnostics, Shanghai Haini Pharmaceutical, Shenzhen China Resources Gosun Pharmaceutical, Shionogi, Sinovant Sciences, SpeeDx, Spero Therapeutics, Strides Pharma Science, Summit Therapeutics, Suzhou NeuPharma, Swixx Biopharma, Tabuk Pharmaceutical, Taiba, TaiGen Biotechnology, TB Alliance, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, The Medicines Company, Theravance Biopharma, Thermo Fisher Scientific, TLC BioSciences, Trellis Bioscience, University of Bergen, University of California Los Angeles, University of Florida, University of Liverpool, University of Melbourne, University of New South Wales, University of Queensland, University of Technology Sydney, University of Zurich, US Army Medical Research Institute of Infectious Diseases, UTILITY Therapeutics, UT Southwestern Medical Center, VenatoRx, Verity Pharmaceuticals, Vertex Pharmaceuticals, Vinnova, Warp Drive Bio, Wellcome Trust, Wuxi Apptec Laboratory Services, X-Biotix Therapeutics, X-chem, Xellia Pharmaceuticals, ZAI Laboratory, Zoetis, Zydus Cadila

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.